Allison Kurian, MD, of Stanford University School of Medicine, discusses pressing questions about the clinical utility and value of extended genomic testing and other forms of precision medicine.
Craig Earle, MD, of Canada’s Institute for Clinical Evaluative Sciences, summarizes abstracts discussed in a ticketed session that he co-chaired on this key topic. (Abstracts 173, 174, 175)
Steven Shak, MD, of Genomic Health, discusses mortality among patients with early-stage hormone receptor–positive invasive breast cancer in the SEER database who were treated based on the 21-gene Recurrence Score results (Abstract 176).
Robert Miller, MD, ASCO’S Vice President of Quality and Guidelines, discusses CancerLinQ, the “big data” technology platform, and implementation of a rapid learning system for oncology based on Institute of Medicine principles.
Joseph O. Jacobson, MD, of the Dana-Farber Cancer Institute, discusses a session he co-chaired on the thorny questions of how best to improve cancer care.
Lawrence N. Shulman, MD, of the University of Pennsylvania, discusses his paper, which explores lessons learned from analyses of the National Cancer Data Base. (Abstract 173)
